Eli Lilly and Co  

(Public, NYSE:LLY)   Watch this stock  
Find more results for LLY
71.73
-0.38 (-0.53%)
After Hours: 71.73 0.00 (0.00%)
Jan 27, 4:30PM EST  
NYSE real-time data - Disclaimer
Currency in USD
Range 71.45 - 72.14
52 week 52.29 - 75.10
Open 71.76
Vol / Avg. 3.65M/4.98M
Mkt cap 80.37B
P/E 28.71
Div/yield 0.50/2.79
EPS 2.50
Shares 1.11B
Beta 0.42
Inst. own 77%
Apr 23, 2015
Q1 2015 Eli Lilly and Co Earnings Release - 9:30AM EDT - Add to calendar
Apr 23, 2015
Q1 2015 Eli Lilly and Co Earnings Call - 9:00AM EDT - Add to calendar
Jan 30, 2015
Q4 2014 Eli Lilly and Co Earnings Release - 9:30AM EST - Add to calendar
Jan 30, 2015
Q4 2014 Eli Lilly and Co Earnings Conference Call - 9:00AM EST - Add to calendar
Jan 13, 2015
Eli Lilly and Co at JPMorgan Healthcare Conference
Jan 7, 2015
Eli Lilly and Co Strategy Update and 2015 Financial Guidance Call
Nov 12, 2014
Eli Lilly and Co at Credit Suisse Healthcare Conference
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '14) 2013
Net profit margin 10.27% 20.27%
Operating margin 11.53% 23.24%
EBITD margin - 29.76%
Return on average assets 5.76% 13.45%
Return on average equity 11.26% 28.92%
Employees 39,510 -
CDP Score - 86 B

Address

Lilly Corporate Center
INDIANAPOLIS, IN 46285
United States - Map
+1-317-2762000 (Phone)
+1-317-2763492 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
About Company - Wikipedia

Description

Eli Lilly and Company discovers, develops, manufactures, and sells products in two business segments human pharmaceutical products and animal health products. The Company manufactures and distributes its products through facilities in the United States, Puerto Rico and 11 other countries. Its animal health business, operating through its Elanco division, develops, manufactures, and markets products for both food animals and companion animals. The Company�s products are Humulin, Jentadueto, Axiron, Cymbalta, Strattera, Amyvid, Gemzar, Erbitux, Effient, ReoPro, Posilac, Posilac and Surmax. Its products in Late-Stage are Dulaglutide, Empagliflozin, Ramucirumab, Evacetrapib, Necitumumab, Tanezumab, Edivoxetine, Liprotamase and Ramucirumab.

Officers and directors

John C. Lechleiter Ph.D. Chairman of the Board, President, Chief Executive Officer
Age: 61
Bio & Compensation  - Reuters
Derica W. Rice Chief Financial Officer, Executive Vice President - Global Services
Age: 49
Bio & Compensation  - Reuters
Maria A. Crowe President - Manufacturing Operations
Age: 54
Bio & Compensation  - Reuters
Jan M. Lundberg Ph.D. Executive Vice President - Science and Technology, President - Lilly Research Laboratories
Age: 60
Bio & Compensation  - Reuters
Melissa S. Barnes Senior Vice President - Enterprise Risk Management and Chief Ethics and Compliance Officer
Age: 45
Bio & Compensation  - Reuters
Michael J. Harrington Senior Vice President, General Counsel
Age: 51
Bio & Compensation  - Reuters
Stephen F. Fry Senior Vice President - Human Resources and Diversity
Age: 48
Bio & Compensation  - Reuters
Darren J. Carroll Senior Vice President - Corporate Business Development
Bio & Compensation  - Reuters
Enrique A. Conterno Senior Vice President and President - Lilly Diabetes
Age: 47
Bio & Compensation  - Reuters
Susan Mahony Ph.D. Senior Vice President and President - Lilly Oncology
Age: 49
Bio & Compensation  - Reuters